Curated News
By: NewsRamp Editorial Staff
March 02, 2026
Scinai Extends PinCell Option, Seeks €12M EU Grant for Skin Disease Therapy
TLDR
- Scinai Immunotherapeutics secures extended acquisition timeline and €12M non-dilutive funding for PC111, gaining financial advantage and extended strategic flexibility in drug development.
- Scinai amended its PinCell option agreement to extend deadlines to 2026 and submitted a revised SMART Path application for €12M funding to support PC111's R&D program.
- Scinai's PC111 development targets pemphigus vulgaris and Stevens-Johnson Syndrome, potentially improving treatment options for patients with these serious autoimmune conditions.
- Scinai is developing a fully human monoclonal antibody targeting soluble Fas Ligand, representing an innovative approach to treating rare autoimmune diseases.
Impact - Why it Matters
This development matters because it represents a critical financing and strategic milestone for a potential treatment addressing severe, underserved medical conditions. Pemphigus vulgaris and SJS/TEN are devastating disorders with limited treatment options; SJS/TEN, in particular, has a high mortality rate and often leaves survivors with long-term complications. The €12 million in non-dilutive funding sought from the European SMART Path program is significant—it would fund 80% of the R&D for PC111 without requiring equity dilution or repayment, preserving shareholder value while de-risking the path to clinical trials. For patients, this news signals progress toward a targeted therapy that could address the underlying immune dysfunction in these diseases, potentially offering a more effective and safer alternative to current broad immunosuppressants. For the biotech investment community, it demonstrates Scinai's execution capability in navigating complex regulatory funding pathways and structuring strategic acquisitions (PinCell) to bolster its pipeline. Success in securing this grant and advancing PC111 could validate Scinai's research approach, attract partnership interest for its NanoAb platform, and ultimately bring a novel treatment closer to patients who currently face dire prognoses.
Summary
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company with both a contract development and manufacturing organization (CDMO) business and an immunology research pipeline, has taken significant steps to advance its acquisition of PinCell S.r.l. and secure crucial funding for a promising therapeutic candidate. The company announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition, extending the option condition deadline to August 31, 2026, and the exercise period to September 30, 2026. This strategic move aligns with the company's parallel submission of a revised application under the European Funds for the Modern Economy SMART Path program, seeking €12 million in non-dilutive, non-repayable funding to support an integrated R&D program for its drug candidate PC111.
The core of this news revolves around PC111, a fully human monoclonal antibody designed to target soluble Fas Ligand for the treatment of two serious and often life-threatening conditions: pemphigus vulgaris, a rare autoimmune blistering disease, and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), severe skin reactions often triggered by medications. The requested €12 million grant would represent 80% co-financing for a total €15 million program aimed at advancing PC111 toward early clinical development and achieving human proof of concept. The funding timeline is critical, as the three- to four-month grant review period is now synchronized with the extended acquisition option deadlines, creating a cohesive strategic window for Scinai.
Beyond the specific drug development, the announcement highlights Scinai's dual business model. Its wholly owned CDMO unit provides fee-for-service development and manufacturing to other biotech and pharmaceutical companies, while the company simultaneously advances its own immunology pipeline, which includes PC111 and next-generation NanoAb-based programs. The press release was distributed by MissionIR (“MIR”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN (Investor Brand Network), which assists IR firms with syndicated content to enhance company visibility. MissionIR provides services like access to wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, and social media distribution to millions of followers, aiming to cut through market noise and provide clients with unparalleled recognition and brand awareness. For more details, readers can view the full press release.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Extends PinCell Option, Seeks €12M EU Grant for Skin Disease Therapy
